104 related articles for article (PubMed ID: 33471382)
21. Regional Overlap of Pathologies in Lewy Body Disorders.
Colom-Cadena M; Grau-Rivera O; Planellas L; Cerquera C; Morenas E; Helgueta S; Muñoz L; Kulisevsky J; Martí MJ; Tolosa E; Clarimon J; Lleó A; Gelpi E
J Neuropathol Exp Neurol; 2017 Mar; 76(3):216-224. PubMed ID: 28395086
[TBL] [Abstract][Full Text] [Related]
22. Alpha-synuclein-positive structures in cases with sporadic Alzheimer's disease: morphology and its relationship to tau aggregation.
Arai Y; Yamazaki M; Mori O; Muramatsu H; Asano G; Katayama Y
Brain Res; 2001 Jan; 888(2):287-296. PubMed ID: 11150486
[TBL] [Abstract][Full Text] [Related]
23. Associations between ZnT3, tau pathology, agitation, and delusions in dementia.
Whitfield DR; Francis PT; Ballard C; Williams G
Int J Geriatr Psychiatry; 2018 Aug; 33(8):1146-1152. PubMed ID: 29856089
[TBL] [Abstract][Full Text] [Related]
24. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.
Noguchi-Shinohara M; Tokuda T; Yoshita M; Kasai T; Ono K; Nakagawa M; El-Agnaf OM; Yamada M
Brain Res; 2009 Jan; 1251():1-6. PubMed ID: 19071095
[TBL] [Abstract][Full Text] [Related]
25. Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies.
Colom-Cadena M; Gelpi E; Charif S; Belbin O; Blesa R; Martí MJ; Clarimón J; Lleó A
J Neuropathol Exp Neurol; 2013 Dec; 72(12):1203-12. PubMed ID: 24226269
[TBL] [Abstract][Full Text] [Related]
26. Neuropathological investigation of hypocretin expression in brains of dementia with Lewy bodies.
Kasanuki K; Iseki E; Kondo D; Fujishiro H; Minegishi M; Sato K; Katsuse O; Hino H; Kosaka K; Arai H
Neurosci Lett; 2014 May; 569():68-73. PubMed ID: 24704327
[TBL] [Abstract][Full Text] [Related]
27. Associations Between APOE Variants, Tau and α-Synuclein.
Rodriguez-Vieitez E; Nielsen HM
Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
[TBL] [Abstract][Full Text] [Related]
28. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.
Kasuga K; Tokutake T; Ishikawa A; Uchiyama T; Tokuda T; Onodera O; Nishizawa M; Ikeuchi T
J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):608-10. PubMed ID: 20522869
[TBL] [Abstract][Full Text] [Related]
29. Alpha-synuclein inclusions in Alzheimer and Lewy body diseases.
Mukaetova-Ladinska EB; Hurt J; Jakes R; Xuereb J; Honer WG; Wischik CM
J Neuropathol Exp Neurol; 2000 May; 59(5):408-17. PubMed ID: 10888371
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous quantification of tau and α-synuclein in cerebrospinal fluid by high-resolution mass spectrometry for differentiation of Lewy Body Dementia from Alzheimer's Disease and controls.
Viodé A; Epelbaum S; Benyounes I; Verny M; Dubois B; Junot C; Fenaille F; Lamari F; Becher F
Analyst; 2019 Oct; 144(21):6342-6351. PubMed ID: 31553333
[TBL] [Abstract][Full Text] [Related]
31. Relationship in the formation process between neurofibrillary tangles and Lewy bodies in the hippocampus of dementia with Lewy bodies brains.
Iseki E; Takayama N; Marui W; Uéda K; Kosaka K
J Neurol Sci; 2002 Mar; 195(1):85-91. PubMed ID: 11867079
[TBL] [Abstract][Full Text] [Related]
32. Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage.
Bousiges O; Philippi N; Lavaux T; Perret-Liaudet A; Lachmann I; Schaeffer-Agalède C; Anthony P; Botzung A; Rauch L; Jung B; de Sousa PL; Demuynck C; Martin-Hunyadi C; Cretin B; Blanc F
Alzheimers Res Ther; 2020 Sep; 12(1):120. PubMed ID: 32993772
[TBL] [Abstract][Full Text] [Related]
33. Bispecific Tau Antibodies with Additional Binding to C1q or Alpha-Synuclein.
Quint WH; Matečko-Burmann I; Schilcher I; Löffler T; Schöll M; Burmann BM; Vogels T
J Alzheimers Dis; 2021; 80(2):813-829. PubMed ID: 33579845
[TBL] [Abstract][Full Text] [Related]
34. Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.
Abdelnour C; van Steenoven I; Londos E; Blanc F; Auestad B; Kramberger MG; Zetterberg H; Mollenhauer B; Boada M; Aarsland D;
Mov Disord; 2016 Aug; 31(8):1203-8. PubMed ID: 27296778
[TBL] [Abstract][Full Text] [Related]
35. Pathologic evaluation of the supraoptic and paraventricular nuclei in dementia.
Diodati D; Cyn-Ang L; Kertesz A; Finger E
Can J Neurol Sci; 2012 Mar; 39(2):213-9. PubMed ID: 22343156
[TBL] [Abstract][Full Text] [Related]
36. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
[TBL] [Abstract][Full Text] [Related]
37. Commentary to "Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease".
Mandal PK; Pettegrew JW
Neurochem Res; 2008 Jun; 33(6):1168. PubMed ID: 18049892
[No Abstract] [Full Text] [Related]
38. MAPT H1 haplotype is associated with enhanced α-synuclein deposition in dementia with Lewy bodies.
Colom-Cadena M; Gelpi E; Martí MJ; Charif S; Dols-Icardo O; Blesa R; Clarimón J; Lleó A
Neurobiol Aging; 2013 Mar; 34(3):936-42. PubMed ID: 22819391
[TBL] [Abstract][Full Text] [Related]
39. Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels.
Slaets S; Vanmechelen E; Le Bastard N; Decraemer H; Vandijck M; Martin JJ; De Deyn PP; Engelborghs S
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S290-8. PubMed ID: 24439167
[TBL] [Abstract][Full Text] [Related]
40. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies.
Muntané G; Dalfó E; Martinez A; Ferrer I
Neuroscience; 2008 Apr; 152(4):913-23. PubMed ID: 18343584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
